Literature DB >> 11885549

Laboratory-confirmed reinfections with Bordetella pertussis.

F G A Versteegh1, J F P Schellekens, A F Nagelkerke, J J Roord.   

Abstract

UNLABELLED: Susceptibility to infection with Bordetella pertussis re-emerges several years after pertussis vaccination. However, the duration of immunity after natural infection with B. pertussis, postulated to be lifelong, is not known. In an ongoing study, the longitudinal course of pertussis antibodies in patients who have had laboratory-confirmed pertussis is being followed using sera obtained at irregular intervals. In 4 patients a reinfection with Bordetella pertussis is described respectively 7 (patient A), 12 (patients B and C) and 3.5 (patient D) y after the first infection. It seems that the longer the interval between the infections the more severe the complaints.
CONCLUSION: To the authors' knowledge. these are the first patients in whom symptomatic reinfection with B. pertussis has definitely been proven by laboratory confirmation of both episodes. Bordetella pertussis infection should be considered in patients with symptoms of typical or atypical whooping cough, irrespective of their vaccination status or previous whooping cough.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11885549     DOI: 10.1080/080352502753458030

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  18 in total

Review 1.  The pertussis enigma: reconciling epidemiology, immunology and evolution.

Authors:  Matthieu Domenech de Cellès; Felicia M G Magpantay; Aaron A King; Pejman Rohani
Journal:  Proc Biol Sci       Date:  2016-01-13       Impact factor: 5.349

2.  Imperfect vaccine-induced immunity and whooping cough transmission to infants.

Authors:  Jennie Lavine; Hélène Broutin; Eric T Harvill; Ottar N Bjørnstad
Journal:  Vaccine       Date:  2010-10-27       Impact factor: 3.641

3.  Establishment of diagnostic cutoff points for levels of serum antibodies to pertussis toxin, filamentous hemagglutinin, and fimbriae in adolescents and adults in the United States.

Authors:  Andrew L Baughman; Kristine M Bisgard; Kathryn M Edwards; Dalya Guris; Michael D Decker; Kathy Holland; Bruce D Meade; Freyja Lynn
Journal:  Clin Diagn Lab Immunol       Date:  2004-11

4.  Natural immune boosting in pertussis dynamics and the potential for long-term vaccine failure.

Authors:  Jennie S Lavine; Aaron A King; Ottar N Bjørnstad
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-21       Impact factor: 11.205

5.  Brief Report: Seroprevalence of Pertussis Infection in HIV-Infected Adults in the United States.

Authors:  Stephanie B Troy; Alexandria E-B Rossheim; DaShaunda D Hilliard; Tina D Cunningham
Journal:  J Acquir Immune Defic Syndr       Date:  2016-11-01       Impact factor: 3.731

Review 6.  What Is Wrong with Pertussis Vaccine Immunity? The Problem of Waning Effectiveness of Pertussis Vaccines.

Authors:  Nicolas Burdin; Lori Kestenbaum Handy; Stanley A Plotkin
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-12-01       Impact factor: 10.005

7.  Incidence and reproduction numbers of pertussis: estimates from serological and social contact data in five European countries.

Authors:  Mirjam Kretzschmar; Peter F M Teunis; Richard G Pebody
Journal:  PLoS Med       Date:  2010-06-22       Impact factor: 11.069

Review 8.  Association Between Vaccine Refusal and Vaccine-Preventable Diseases in the United States: A Review of Measles and Pertussis.

Authors:  Varun K Phadke; Robert A Bednarczyk; Daniel A Salmon; Saad B Omer
Journal:  JAMA       Date:  2016-03-15       Impact factor: 56.272

Review 9.  Pertussis: Microbiology, Disease, Treatment, and Prevention.

Authors:  Paul E Kilgore; Abdulbaset M Salim; Marcus J Zervos; Heinz-Josef Schmitt
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

10.  Estimating the duration of pertussis immunity using epidemiological signatures.

Authors:  Helen J Wearing; Pejman Rohani
Journal:  PLoS Pathog       Date:  2009-10-30       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.